SCHEMBL23323614

SCHEMBL23323614

CN1CCCC(N(C)c2ccccc2C2CCCN2)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.36
CHRM2 P08172 4/20 0.36
CHRM1 P11229 4/20 0.36
KCNH2 Q12809 3/20 0.36
DRD3 P35462 3/20 0.36
ADRA2A P08913 2/20 0.36
DRD1 P21728 2/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
ADRA1A P35348 2/20 0.36
OPRM1 P35372 2/20 0.36
HRH3 Q9Y5N1 2/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
CYP2D6 P10635 1/20 0.36
TSHR P16473 1/20 0.36
HTR1A P08908 1/20 0.36
TBXA2R P21731 1/20 0.36
SIGMAR1 Q99720 2/20 0.35
ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23323616 0.94 TAAR1 (0.37) TAAR1CHRM1SLC6A2SIGMAR1ATM
SCHEMBL23323163 0.79 CHRNB2 (0.44) CHRM2CHRM1KCNH2DRD3ADRA2A
SCHEMBL28526280 0.77 DRD2 (0.43) TAAR1CHRM2CHRM1KCNH2DRD3
SCHEMBL23323611 0.76 HTR6 (0.39) TAAR1CHRM1HTR6
SCHEMBL30078318 0.75 MEN1 (0.42) TAAR1CHRM2CHRM1CYP2D6MEN1
SCHEMBL23323175 0.75 MEN1 (0.42) TAAR1CHRM2CHRM1CYP2D6MEN1
SCHEMBL24774495 0.75 ATM (0.35) CHRM2CHRM1KCNH2DRD3ADRA2A
SCHEMBL24774542 0.75 ATM (0.35) CHRM2CHRM1KCNH2DRD3ADRA2A
SCHEMBL23323170 0.73 CHRNB2 (0.44) CHRM2CHRM1CHRM5CHRM3CHRM4
SCHEMBL23487422 0.72 KDM4E (0.49) TAAR1CHRM2CHRM1SIGMAR1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376104-A1 Bcl-2 Inhibitors BEIGENE LTD. (KY) 2024-11-14 US disclosed
US-11420968-B2 Bcl-2 inhibitors BEIGENE, LTD. (KY) 2022-08-23 US disclosed
WO-2021083135-A1 Bcl-2 INHIBITORS BEIGENE, LTD. (KY) 2021-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11420968-B2 Bcl-2 inhibitors BCL2, BCL2L1, BCL2L2 TAAR1 4675/4885CHRM2 4863/4885CHRM1 4883/4885
US-20240376104-A1 Bcl-2 Inhibitors BCL2, BCL2L1, BCL2L2 TAAR1 4675/4885CHRM2 4863/4885CHRM1 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.